Vanguard Group Inc Biocryst Pharmaceuticals Inc Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 17,676,767 shares of BCRX stock, worth $107 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,676,767
Previous 17,763,720
0.49%
Holding current value
$107 Million
Previous $106 Million
15.61%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BCRX
# of Institutions
258Shares Held
182MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$112 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$106 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$79.3 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$61.6 Million0.65% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.53MShares$39.7 Million3.48% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.13B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...